These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 25734377

  • 1. Peroxisome Proliferator-Activated Receptor γ (PPARγ) and Ligand Choreography: Newcomers Take the Stage.
    Garcia-Vallvé S, Guasch L, Tomas-Hernández S, del Bas JM, Ollendorff V, Arola L, Pujadas G, Mulero M.
    J Med Chem; 2015 Jul 23; 58(14):5381-94. PubMed ID: 25734377
    [Abstract] [Full Text] [Related]

  • 2. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
    Li Y, Wang Z, Furukawa N, Escaron P, Weiszmann J, Lee G, Lindstrom M, Liu J, Liu X, Xu H, Plotnikova O, Prasad V, Walker N, Learned RM, Chen JL.
    J Biol Chem; 2008 Apr 04; 283(14):9168-76. PubMed ID: 18263587
    [Abstract] [Full Text] [Related]

  • 3. Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.
    Tan Y, Muise ES, Dai H, Raubertas R, Wong KK, Thompson GM, Wood HB, Meinke PT, Lum PY, Thompson JR, Berger JP.
    Mol Pharmacol; 2012 Jul 04; 82(1):68-79. PubMed ID: 22496518
    [Abstract] [Full Text] [Related]

  • 4. Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma.
    Sauer S.
    Trends Pharmacol Sci; 2015 Oct 04; 36(10):688-704. PubMed ID: 26435213
    [Abstract] [Full Text] [Related]

  • 5. Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPARγ phosphorylation.
    Jang JY, Kim H, Kim HJ, Suh SW, Park SB, Han BW.
    Sci Rep; 2019 Aug 01; 9(1):11168. PubMed ID: 31371757
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds.
    Porskjær Christensen L, Bahij El-Houri R.
    Molecules; 2018 Sep 22; 23(10):. PubMed ID: 30248999
    [Abstract] [Full Text] [Related]

  • 12. L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation.
    Xie X, Zhou X, Chen W, Long L, Li W, Yang X, Li S, Wang L.
    Biochim Biophys Acta; 2015 Jan 22; 1850(1):62-72. PubMed ID: 25305559
    [Abstract] [Full Text] [Related]

  • 13. Rational screening of peroxisome proliferator-activated receptor-γ agonists from natural products: potential therapeutics for heart failure.
    Chen R, Wan J, Song J, Qian Y, Liu Y, Gu S.
    Pharm Biol; 2017 Dec 22; 55(1):503-509. PubMed ID: 27937122
    [Abstract] [Full Text] [Related]

  • 14. PPARγ signaling and emerging opportunities for improved therapeutics.
    Wang S, Dougherty EJ, Danner RL.
    Pharmacol Res; 2016 Sep 22; 111():76-85. PubMed ID: 27268145
    [Abstract] [Full Text] [Related]

  • 15. N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo.
    Bhalla K, Hwang BJ, Choi JH, Dewi R, Ou L, Mclenithan J, Twaddel W, Pozharski E, Stock J, Girnun GD.
    J Biol Chem; 2011 Dec 02; 286(48):41626-41635. PubMed ID: 21979952
    [Abstract] [Full Text] [Related]

  • 16. Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.
    Seto S, Okada K, Kiyota K, Isogai S, Iwago M, Shinozaki T, Kitamura Y, Kohno Y, Murakami K.
    J Med Chem; 2010 Jul 08; 53(13):5012-24. PubMed ID: 20527969
    [Abstract] [Full Text] [Related]

  • 17. Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ.
    Jang JY, Bae H, Lee YJ, Choi YI, Kim HJ, Park SB, Suh SW, Kim SW, Han BW.
    Sci Rep; 2018 Jan 08; 8(1):31. PubMed ID: 29311579
    [Abstract] [Full Text] [Related]

  • 18. GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain.
    Amato AA, Rajagopalan S, Lin JZ, Carvalho BM, Figueira AC, Lu J, Ayers SD, Mottin M, Silveira RL, Souza PC, Mourão RH, Saad MJ, Togashi M, Simeoni LA, Abdalla DS, Skaf MS, Polikparpov I, Lima MC, Galdino SL, Brennan RG, Baxter JD, Pitta IR, Webb P, Phillips KJ, Neves FA.
    J Biol Chem; 2012 Aug 10; 287(33):28169-79. PubMed ID: 22584573
    [Abstract] [Full Text] [Related]

  • 19. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.
    Choi JH, Banks AS, Kamenecka TM, Busby SA, Chalmers MJ, Kumar N, Kuruvilla DS, Shin Y, He Y, Bruning JB, Marciano DP, Cameron MD, Laznik D, Jurczak MJ, Schürer SC, Vidović D, Shulman GI, Spiegelman BM, Griffin PR.
    Nature; 2011 Sep 04; 477(7365):477-81. PubMed ID: 21892191
    [Abstract] [Full Text] [Related]

  • 20. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK, Chae YN, Kim HS, Choi SH, Son MH, Kim SH, Kim JK, Moon HS, Park SK, Shin YA, Kim JG, Lee CH, Lim JI, Shin CY.
    Arch Pharm Res; 2009 May 04; 32(5):721-7. PubMed ID: 19471887
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.